JA
Therapeutic Areas
Ovid Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OV329 | Treatment-resistant seizures | Phase 1 |
| OV350 | Undisclosed CNS disorders | Preclinical |
| OV882 | SYNGAP1-related intellectual disability | Research |
| OV4071 | Undisclosed CNS disorders | Research |
| Soticlestat (OV935/TAK-935) | Dravet Syndrome, Lennox-Gastaut Syndrome | Phase 3 |
Leadership Team at Ovid Therapeutics
MA
Meg Alexander
President & Chief Executive Officer
ZZ
Zhong Zhong, Ph.D.
Chief Scientific Officer
TP
Thomas Perone
Chief Legal Officer & Corporate Secretary
RC
R. Cory
SVP, Head of Corporate Affairs & Investor Relations
JM
Jeremy M. Levin, D.Phil, MB BChir
Co-founder and Executive Chairman
RJ
Robert J. Gould, Ph.D.
Director
BD
Barbara Duncan
Director
TD
Timothy Daly
Director